Accessibility Menu
Maravai LifeSciences logo

Maravai LifeSciences(NASDAQ) MRVI

Market Cap$1.08BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-76%
5 Year-88%
1 Year+188%
1 Month+3%
$8.30
+14.96%
+1.08Today
Maravai LifeSciences last closing stock price
MetricPriceDate
Last closeUSD 7.222026-08-19
Maravai LifeSciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+24.91%USD 5.782026-08-12
1 month+3.29%USD 6.992026-07-20
3 month+61.16%USD 4.482026-05-21
Year to date+122.15%USD 3.252025-12-31
1 year+187.65%USD 2.512025-08-19
3 year-28.59%USD 10.112023-08-18
5 year-88.09%USD 60.622021-08-20
Since inception-75.81%USD 29.852020-11-20

Maravai LifeSciences Financials at a Glance

Market Cap

$1.08BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$208.78M

Net Income (TTM)

-$77.39M

EPS (TTM)

-$0.53

P/E Ratio

-13.57

Dividend

$0.00

Beta (Volatility)

1.12 (Average)

Price

$8.30

Volume

6,227,622.288

Open

$7.44

Previous Close

$7.22

Daily Range

$7.38 - $8.22

52-Week Range

$2.28 - $8.22

Estimated Earnings Date

Nov 5, 2026

MRVI News

Business people shaking hands in conference room.

2 Healthcare Companies That Could Be Acquired Within 5 Years

David Jagielski, CPAFeb 7, 2023
biotech worker on assembly line

2 Biotech Stocks You Can Buy and Hold for the Next Decade

Alex CarchidiNov 28, 2022
scientist looks into microscope while sitting at lab bench

This Fallen Growth Stock Is Still a Wall Street Favorite: Here's Why

Alex CarchidiOct 29, 2022
A couple meeting with an advisor.

3 of the Best Bear Market Buys for August

David Jagielski, CPAAug 5, 2022
A person delivering a presentation.

Forget Robinhood and Buy These 2 Growth Stocks Instead

David Jagielski, CPAApr 6, 2022
two investors look at figures

1 Biotech Stock Investors Should Know About

Alex CarchidiMar 18, 2022
Stethoscope atop 100 dollar bills and pennies

Why Maravai LifeSciences Tumbled Nearly 12% Today

Eric VolkmanSep 10, 2021

MRVI: Motley Fool Moneyball Superscore

41

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Maravai LifeSciences

Maravai helps scientists make new vaccines and medicines. They make building blocks for gene and cell therapies. Their tools help catch impurities during drug manufacturing.

The Building Blocks of Biotech

  • TriLink segment: Provides complex nucleic acids like mRNA and CleanCap capping technology; accounts for 64% of revenue.
  • Cygnus segment: Focuses on biologics safety testing and analytical impurity detection; represents 36% of revenue.
  • CleanCap technology: Proprietary chemical reagents used to stabilize and improve the performance of mRNA-based medicines.
  • Safety testing kits: Analytical tools that detect host cell proteins and other leftover materials during drug production.

Recent Moves and Big Changes

  • Announced the 2025 Corporate Realignment Plan in August 2025 to reduce the workforce and lower costs.
  • Appointed a new Chief Executive Officer and a new Chief Financial Officer in June 2025.
  • Renamed the reportable business segments to TriLink and Cygnus during fiscal year 2025.
  • Incorporated AI technology from Officinae Bio to help customers design and optimize better mRNA sequences.

What Sets Maravai Apart

Maravai operates specialized manufacturing facilities across California, North Carolina, Virginia, and Florida to support global drug production. The company holds exclusive patents for CleanCap technology, which improves the efficiency of messenger RNA manufacturing for its pharmaceutical clients.

The Latest Financial Scorecard

  • Revenue was $49.9 million in Q4 2025, down 11.6% year-over-year.
  • Operating loss narrowed to $6.7 million in Q4 2025, an 82.3% improvement from Q4 2024.
  • Gross profit reached $12.2 million in Q4 2025, down 35.4% from the previous year.
  • Free cash flow worsened to -$24.9 million in Q4 2025, down 21.5% compared to Q4 2024.

The Final Word

Maravai is transforming from a pandemic-focused supplier into a specialized partner for diverse gene therapy developers. The company is currently restructuring its operations to focus on sustainable growth within the biologics safety market.

AI Generated • May 5, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

435

CEO

Bernd Brust

Website

www.maravai.com

Headquarters

San Diego, CA 92121, US

MRVI Financials

Key Financial Metrics (TTM)

Gross Margin

34.61%

Operating Margin

46.02%

Net Income Margin

-37.07%

Return on Equity

-35.42%

Return on Capital

-2.72%

Return on Assets

-12.82%

Earnings Yield

-7.37%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.08BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

148.99M

Volume

6.23M

Avg. Volume

3.02M

Financials (TTM)

Gross Profit

$72.25M

Operating Income

$96.09M

EBITDA

-$57.20M

Operating Cash Flow

-$25.26M

Capital Expenditure

-$9.85M

Free Cash Flow

-$35.11M

Cash & ST Invst.

$70.09M

Total Debt

$176.70M

Maravai LifeSciences Performance Analysis

Maravai LifeSciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 883,001,00010.5%
20232023-12-31USD 288,945,000-67.3%
20242024-12-31USD 259,185,000-10.3%
20252025-12-31USD 185,743,000-28.3%
Maravai LifeSciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-12.2%
Q42025-12-3119.8%
Q12026-03-3132.0%
Q22026-06-30-21.9%
Maravai LifeSciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.677.0%
20232023-12-31USD -0.90N/A
20242024-12-31USD -1.0516.4%
20252025-12-31USD -0.91-13.7%
Maravai LifeSciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3033.3%
Q42025-12-31-38.9%
Q12026-03-3189.8%
Q22026-06-30-213.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$51.44M

+8.5%

Gross Profit

$20.65M

+165.8%

Gross Margin

40.14%

N/A

Market Cap

$1.08BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.59M

N/A

Employees

416

N/A

Net Income

-$12.42M

+68.6%

EBITDA

-$5.21M

+90.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$70.09M

-74.0%

Total Debt

$176.70M

-51.4%

Accounts Receivable

$31.14M

+11.7%

Inventory

$41.23M

-11.7%

Long Term Debt

$175.57M

-50.9%

Short Term Debt

$1.13M

-82.2%

Return on Assets

-12.82%

N/A

Return on Invested Capital

17.00%

N/A

Free Cash Flow

$3.62M

+127.6%

Operating Cash Flow

$3.99M

+138.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KURAKura Oncology, Inc.
$11.89-5.11%
REPLReplimune Group, Inc.
$14.20-4.12%
TYRATyra Biosciences, Inc.
$25.57-4.63%
PRMEPrime Medicine, Inc.
$3.35-5.37%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.77+0.06%
IBITiShares Bitcoin Trust
$40.92+0.06%
SPCXSpace Exploration Technologies
$130.55-0.07%
MRNAModerna
$139.48-0.20%

Questions About MRVI

What is the current price of Maravai LifeSciences?

Maravai LifeSciences is trading at $8.19 per share.

What is the 52-week range for Maravai LifeSciences?

Over the past 52 weeks, Maravai LifeSciences has traded between $2.28 and $8.22.

How much debt does Maravai LifeSciences have?

As of the most recent reporting period, Maravai LifeSciences reported total debt of $176.70M.

How much cash does Maravai LifeSciences have on hand?

Maravai LifeSciences reported $70.58M in cash and cash equivalents in its most recent financial results.

What is Maravai LifeSciences’s dividend yield?

Maravai LifeSciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services